Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of once-weekly subcutaneous and once-daily oral NNC0487-0111 in type 2 diabetes
2023-509412-28-00Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2024
- Modality
- Small Molecules, Peptides
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of amycretin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Jul 2024; status: completed.
02
Drugs
amycretin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2023-509412-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509412-28-00.